Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
This rat study investigated whether BPC 157, a synthetic pentadecapeptide derived from a gastric protein, could protect skeletal muscle tissue from ischemia-reperfusion (I/R) injury. Twenty-four male Wistar rats were divided into four groups (n=6 each): sham surgery, BPC 157 alone, I/R injury alone, and I/R injury treated with BPC 157. I/R was induced by clamping the abdominal aorta for 45 minutes followed by 2 hours of reperfusion; BPC 157 was given intraperitoneally at the end of the ischemia period. The study measured oxidative stress markers (MDA, SOD, TAS, TOS) in serum, gene expression of inflammatory and apoptotic markers (IL-6, HIF-1α, p53, Bcl-2, Bax, Caspase-3) via qRT-PCR, and protein expression (VEGF, eNOS, IL-6, Caspase-3) via immunohistochemistry, alongside histopathological scoring. The authors report that I/R increased oxidative stress, inflammation, and apoptotic signaling, while BPC 157 treatment was associated with reduced oxidative markers, decreased inflammatory and pro-apoptotic gene expression, increased anti-apoptotic Bcl-2, partial restoration of VEGF, and improved muscle histology. Limitations include very small group sizes (n=6), use of a single dose, a single species, and no human data, restricting the generalizability of findings.
Why this grade: The study was conducted entirely in rats (n=24 total; n=6 per group) with no human subjects or clinical data, providing no direct evidence of efficacy in humans.
Ischemia-reperfusion (I/R) injury remains a major complication in peripheral arterial disease, characterized by oxidative stress, inflammation, and apoptosis. Body Protection Compound-157 (BPC 157), a stable gastric pentadecapeptide, has demonstrated cytoprotective properties in multiple tissues. This study aimed to evaluate the protective effects of BPC 157 in a rat model of lower limb I/R injury. Twenty-four male Wistar albino rats were randomized into four groups (n = 6): SHAM, B (BPC 157 only), IR (I/R), and IRB (I/R + BPC 157). I/R was induced by abdominal aortic clamping for 45 min followed by 2 h of reperfusion. BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups. Biochemical markers (MDA, SOD, TAS, TOS) were measured in serum. Gene expression of Il-6, Hif-1α, p53, Bcl-2, Bax, and Casp3 was assessed by qRT-PCR, while immunohistochemistry evaluated VEGF, eNOS, IL-6, and Caspase-3 expression. Histopathological changes were scored with hematoxylin-eosin and Masson's trichrome staining. I/R significantly increased MDA, TOS, p53, Bax, Casp3, Hif-1α, Il-6, and histopathological injury scores, while reducing SOD, TAS, and VEGF expression. Bcl-2 mRNA was not significantly reduced by I/R compared with SHAM; however, BPC 157 significantly increased Bcl-2 expression compared with IR. In the IRB group, BPC 157 reduced MDA and TOS, restored SOD and TAS, downregulated p53, Bax, and Casp3, reduced IL-6 and Caspase-3 immunoreactivity, and partially restored VEGF expression. Histological analysis confirmed improved muscle architecture and reduced collagen deposition in IRB compared with IR. BPC 157 appears to exert protective effects against skeletal muscle I/R injury by attenuating oxidative stress, modulating apoptosis, reducing inflammation, and supporting angiogenic activity. These findings suggest that BPC 157 may represent a potential therapeutic candidate for mitigating reperfusion injury; however, further studies with larger cohorts and dose-response evaluations are required to confirm these effects and establish clinical relevance.
Educational summary of published research — not medical advice. License: cc by-nc-nd. Full text is shown only where licensing permits.